- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Enfortumab Vedotin Demonstrates Additional Mechanisms of Action in UC Models
June 23rd 2020, 4:13pm
In urothelial carcinoma models, enfortumab vedotin-ejfv appeared to promote multiple mechanisms of action such as bystander cell killing, supporting the use of the agent either alone or in combination with pembrolizumab.
Dr. Galsky on Sequencing Questions in Urothelial Cancer
June 23rd 2020, 2:40pm
Matthew Galsky, MD, discusses sequencing questions in urothelial carcinoma.
Suggested Benefit of Novel BTK Inhibitor Observed in MCL Models and in NHL Combo Regimen
June 23rd 2020, 2:17pm
In preclinical models, the novel irreversible BTK inhibitor TG-1701 demonstrated similar activity to ibrutinib in mantle cell lymphoma cell lines and showed additive benefit when combined with ublituximab and umbralisib in non-Hodgkin lymphoma model.
Dr. Shore on Immunotherapy Targeting PSA and PSMA in Biochemically Recurrent Prostate Cancer
June 22nd 2020, 10:00pm
Neal D. Shore, MD, FACS, discusses immunotherapy targeting prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) in biochemically recurrent prostate cancer.
Atezolizumab Regimen Improves OS in Frontline Extensive-Stage Small Cell Lung Cancer, Regardless of Biomarker Status
June 22nd 2020, 9:26pm
The combination of atezolizumab plus carboplatin/etoposide continued to demonstrate an improvement in overall survival versus chemotherapy alone as a frontline treatment for patients with extensive-stage small cell lung cancer.
Tucatinib Demonstrates Potent Activity in HER2-Mutant Tumor Models
June 22nd 2020, 9:05pm
Tucatinib was found to be a potent inhibitor of HER2-mutant signaling in vitro.
Dr. Rintoul on the Importance of MRD Assessment in NSCLC
June 22nd 2020, 9:00pm
Robert Rintoul, BSc, MB ChB, PhD, FRCP, discusses the importance of minimal residual disease assessment in patients with non–small cell lung cancer.
Survivin Isoforms Detection Predicts a Potential Role in Tumor Biology
June 22nd 2020, 6:09pm
Three main survivin isoforms demonstrated the ability to translocate to the surface of plasma membrane in multiple cell types, suggesting a targetable role as a molecular biomarker.
Hispanic Patients With Select Blood Cancers Have Worse Survival Outcomes
June 22nd 2020, 4:01am
Significant differences were seen between Hispanic and non-Hispanic white patients with hematological malignancies in Texas in terms of the age of diagnosis and long-term survival outcomes.
Real-World Data Show Improved Survival With Adjuvant Immunotherapy in Melanoma
June 22nd 2020, 4:01am
The use of adjuvant immunotherapy in patients with resected stage IIIC melanoma resulted in improved survival benefit, according to real-world data from an early analysis of the National Cancer Database.
Early-Onset Cancers Confer a High Risk of Harboring Germline Mutations
June 22nd 2020, 4:01am
Patients 18 to 39 years of age with early-onset cancer had a significantly high risk of harboring germline mutations, suggesting that this population should undergo germline genetic testing, irrespective of tumor type.
iNEST/Atezolizumab Combo Induces Neoantigen-Specific T-Cell Responses in Advanced Solid Tumors
June 22nd 2020, 4:01am
The addition of the individualized neoantigen specific immunotherapy RO7198457 to atezolizumab induced neoantigen-specific T-cell responses, and was found to be well tolerated in patients with advanced solid malignancies.
Lipophilic Statin Use Is Associated With Decreased Mortality in Epithelial Ovarian Cancer
June 22nd 2020, 4:01am
Findings from an observational study of more than 10,000 women with ovarian cancer showed that lipophilic statins were associated with a 43% overall reduction in epithelial ovarian cancer mortality, with declines seen across subtypes.
Isatuximab Triplet Significantly Improves PFS in Relapsed/Refractory Myeloma
June 14th 2020, 7:30pm
European Hematology Association Congress
The triplet therapy of isatuximab-irfc, carfilzomib, and dexamethasone showed a statistically significant improvement in PFS versus carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Mild COVID-19 Symptoms Are Associated with Poorer Outcomes in Sickle Cell Disease
June 14th 2020, 7:14pm
European Hematology Association Congress
Results from a survey of patients in the United Kingdom showed patients with sickle cell disease diagnosed with COVID-19 and who had mild symptoms were more likely to die or require mechanical ventilation than those with more severe symptoms of COVID-19.
Endotheliopathy: A Marker of Progression to Critical Illness in COVID-19
June 14th 2020, 7:11pm
European Hematology Association Congress
Endotheliopathy represents a marker of progression to critical illness in patients with COVID-19 infection and soluble thrombomodulin segregates with mortality.
Ropeginterferon Alfa-2b Helps Maintain Hematocrit Control for Low-Risk Polycythemia Vera
June 14th 2020, 7:00pm
European Hematology Association Congress
More patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b were able to maintain hematocrit levels at or below 45% compared with those who received monthly phlebotomy alone.
Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia
June 14th 2020, 6:24pm
European Hematology Association Congress
Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.
Dr. Talati on Real-World Data With Venetoclax Combinations in AML
June 13th 2020, 9:29pm
European Hematology Association Congress
Chetasi Talati, MD, discusses the ongoing safety analysis of venetoclax (Venclexta)-based combinations in patients with newly diagnosed acute myeloid leukemia.
Eprenetapopt/Azacitidine Shows Encouraging Responses in High-Risk MDS/AML
June 13th 2020, 7:30pm
European Hematology Association Congress
The combination of eprenetapopt and azacitidine led to high objective response rates and complete response rates in patients with TP53-mutated myelodysplastic syndrome and acute myeloid leukemia.